These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 27842250)

  • 1. The lived experience of interferon-free treatments for hepatitis C: A thematic analysis.
    Whiteley D; Whittaker A; Elliott L; Cunningham-Burley S
    Int J Drug Policy; 2016 Dec; 38():21-28. PubMed ID: 27842250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C in a new therapeutic era: Recontextualising the lived experience.
    Whiteley D; Whittaker A; Elliott L; Cunningham-Burley S
    J Clin Nurs; 2018 Jul; 27(13-14):2729-2739. PubMed ID: 28960567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The experience of interferon-based treatments for hepatitis C infection.
    Hopwood M; Treloar C
    Qual Health Res; 2005 May; 15(5):635-46. PubMed ID: 15802540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.
    Vespasiani-Gentilucci U; Galati G; Gallo P; De Vincentis A; Riva E; Picardi A
    World J Gastroenterol; 2015 Jun; 21(24):7412-26. PubMed ID: 26139987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First and Foremost Battle the Virus: Eliciting Patient Preferences in Antiviral Therapy for Hepatitis C Using a Discrete Choice Experiment.
    Mühlbacher A; Bethge S
    Value Health; 2016; 19(6):776-787. PubMed ID: 27712705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
    Yu ML
    J Gastroenterol Hepatol; 2017 Aug; 32(8):1436-1442. PubMed ID: 28124463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation.
    Su H; Liu Z; Sun Y; Li H; Zhou S; Zhou X; Gao Y; Tang R; Zhang D; Zhang M
    Ann Transplant; 2015 May; 20():263-8. PubMed ID: 25975740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing expense and expectation in a treatment revolution: Problematizing prioritisation through an exploration of hepatitis C treatment 'benefit'.
    Harris M
    Int J Drug Policy; 2017 Sep; 47():161-168. PubMed ID: 28455145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Benefits of a preventive psychiatric accompaniment in patients Hepatitis C Virus seropositive (HCV): prospective study concerning 39 patients].
    Lang JP; Meyer N; Doffoel M
    Encephale; 2003; 29(4 Pt 1):362-5. PubMed ID: 14615706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection.
    Hopwood M; Treloar C
    Int J Drug Policy; 2007 Oct; 18(5):374-80. PubMed ID: 17854725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perspectives of a self-selected sample of former patients on the long-term health outcomes of interferon-based hepatitis C treatments: an exploratory study.
    Hopwood M
    Psychol Health Med; 2013; 18(6):742-50. PubMed ID: 23458315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
    Wyles DL
    J Infect Dis; 2013 Mar; 207 Suppl 1():S33-9. PubMed ID: 23390303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perception.
    Safo SA; Batchelder A; Peyser D; Litwin AH
    Harm Reduct J; 2015 Jun; 12():20. PubMed ID: 26092261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
    Horváth G; Tolvaj G; Halász T; Stotz G
    Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
    Faisal N; Bilodeau M; Aljudaibi B; Hirsch G; Yoshida EM; Hussaini T; Ghali MP; Congly SE; Ma MM; Leonard J; Cooper C; Peltekian K; Renner EL; Lilly LB
    Transplantation; 2016 May; 100(5):1059-65. PubMed ID: 26950722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel interferons for treatment of hepatitis C virus.
    Clark V; Nelson DR
    Clin Liver Dis; 2009 Aug; 13(3):351-63. PubMed ID: 19628153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus infection: looking for interferon free regimens.
    González-Moreno J; Payeras-Cifre A
    ScientificWorldJournal; 2013; 2013():825375. PubMed ID: 23710151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA.
    Shiratori Y; Yokosuka O; Nakata R; Ihori M; Hirota K; Katamoto T; Unuma T; Okano K; Ikeda Y; Hirano M; Kawase T; Takano S; Matsumoto K; Ohashi Y; Omata M
    Hepatology; 1999 May; 29(5):1573-80. PubMed ID: 10216145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of Sjögren syndrome associated with hepatitis C virus when chronic hepatitis C is treated by interferon or the association of interferon and ribavirin].
    Doffoël-Hantz V; Loustaud-Ratti V; Ramos-Casals M; Alain S; Bezanahary H; Liozon E; Fauchais AL; Vidal E
    Rev Med Interne; 2005 Feb; 26(2):88-94. PubMed ID: 15710254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of acute hepatitis C in breast cancer patient: a case report.
    Matovina-Brko G; Ruzic M; Fabri M; Popovic L; Kolarov-Bjelobrk I; Trifunovic J; Petkovic D
    J Chemother; 2014 Jun; 26(3):180-3. PubMed ID: 24621156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.